Incidence and Clinical Presentation of Moderate to Severe Graves' Orbitopathy in a Danish Population before and after Iodine Fortification of Salt

被引:96
|
作者
Laurberg, Peter [1 ]
Berman, Dalia C. [2 ]
Pedersen, Inge Bulow [1 ]
Andersen, Stig [1 ]
Carle, Allan [1 ]
机构
[1] Aarhus Univ Hosp, Dept Endocrinol & Med, Aalborg Hosp, DK-9000 Aalborg, Denmark
[2] Aarhus Univ Hosp, Dept Ophthalmol, Aalborg Hosp, DK-9000 Aalborg, Denmark
来源
关键词
EYE CHANGES; OPHTHALMOPATHY; DISEASE; CLASSIFICATION; HYPERTHYROIDISM; EPIDEMIOLOGY; IODIZATION; MANAGEMENT; CRITERIA; DENMARK;
D O I
10.1210/jc.2012-1275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Population-based data on the incidence and clinical presentation of moderate to severe Graves' orbitopathy (GO) are scarce, and virtually nothing is known on the effect of an iodization program on the incidence and presentation of GO. Objective: The objective of the study was to characterize incident moderate to severe GO in North Jutland County, Denmark, during the period 1992-2009, before and after the Danish salt iodization program. Design and Patients: The design of the study was a prospective register of patients with incident moderate to severe GO in a population during 8.9 million persons x years of observation. Setting: The study was conducted at a thyroid-eye clinic of university hospital. Main Outcome Measures: Clinical presentation and incidence before and after the year 2000 initiation of the mandatory Danish iodization of salt were measured. The incidence of GO was related to the incidence of Graves' hyperthyroidism (GH) in the same population. Results: The incidence rate of moderate to severe GO was 16.1/million per year(women: 26.7; men: 5.4), with no change associated with iodization of salt. The moderate to severe GO incidence was 4.9% of the incidence of GH. The incidence rate ratio between women and men with GO(4.9) was not different from the ratio in GH. Compared with GH, only a few patients (< 2%) suffered from moderate and severe GO below the age of 40 yr, whereas GO was relatively common in age groups 40-60 yr (similar to 8%). Conclusions: Approximately 5% of the patients with Graves' disease develop moderate to severe GO, with a similar risk in women and men with Graves' disease. The risk of GO is much higher in patients aged 40-60 yr than in young patients with Graves' disease. Salt iodization was not associated with a change in the incidence of GO. (J Clin Endocrinol Metab 97: 2325-2332, 2012)
引用
收藏
页码:2325 / 2332
页数:8
相关论文
共 21 条
  • [1] Assessment of iodine fortification of salt in the Danish population
    Outzen, Malene
    Lund, Cecilie E.
    Christensen, Tue
    Trolle, Ellen
    Ravn-Haren, Gitte
    [J]. EUROPEAN JOURNAL OF NUTRITION, 2022, 61 (06) : 2939 - 2951
  • [2] Assessment of iodine fortification of salt in the Danish population
    Malene Outzen
    Cecilie E. Lund
    Tue Christensen
    Ellen Trolle
    Gitte Ravn-Haren
    [J]. European Journal of Nutrition, 2022, 61 : 2939 - 2951
  • [3] An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: A prospective population study
    Pedersen, Inge Bulow
    Laurberg, Peter
    Knudsen, Nils
    Jorgensen, Torben
    Perrild, Hans
    Ovesen, Lars
    Rasmussen, Lone Banke
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08): : 3122 - 3127
  • [4] INCIDENCE OF THYROID AUTONOMY AND GRAVES-DISEASE IN BERLIN-BRANDENBURG AREA BEFORE AND AFTER IODINE SALT PROPHYLAXIS
    DECKART, H
    DECKART, E
    BEHRINGER, F
    KUHNE, H
    ADAM, B
    APITZ, H
    EIFLER, H
    GRAMBOW, H
    HANNEMANN, R
    HANS, R
    HASSLER, R
    JORDAN, T
    KLEIN, G
    KUBITSCHEK, I
    KLEINAU, E
    LORECK, I
    VONMECZYNSKI, E
    NEUMANN, A
    PATZWALDT, R
    PECH, A
    RATZKE, M
    UHLIG, C
    [J]. ACTA MEDICA AUSTRIACA, 1990, 17 : 39 - 41
  • [5] Increase in incidence of hyperthyroidism predominantly occurs in young people after iodine fortification of salt in Denmark
    Pedersen, Inge Bulow
    Laurberg, Peter
    Knudsen, Nils
    Jorgensen, Torben
    Perrild, Hans
    Ovesen, Lars
    Rasmussen, Lone Banke
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (10): : 3830 - 3834
  • [6] Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial
    Perez-Moreiras, Jose, V
    Gomez-Reino, Juan J.
    Maneiro, Jose R.
    Perez-Pampin, Eva
    Romo Lopez, Angel
    Rodriguez Alvarez, Fernando M.
    Castillo Laguarta, Jesus M.
    del Estad Cabello, Aurora
    Gessa Sorroche, Maria
    Espana Gregori, Enrique
    Sales-Sanz, Marco
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 195 : 181 - 190
  • [7] Determinants of clinical outcome in patients with moderate/severe Graves' orbitopathy undergoing treatment with parenteral glucocorticoids: a retrospective study
    Le Moli, Rosario
    Naselli, Adriano
    Costanzo, Gabriele
    Piticchio, Tommaso
    Tumino, Dario
    Pellegriti, Gabriella
    Frasca, Francesco
    Belfiore, Antonino
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [8] Thyrotoxicosis after iodine fortification. A 21-year Danish population-based study
    Petersen, Mads
    Knudsen, Nils
    Carle, Allan
    Andersen, Stig
    Jorgensen, Torben
    Perrild, Hans
    Ovesen, Lars
    Rasmussen, Lone Banke
    Thuesen, Betina Heinsbaek
    Pedersen, Inge Bulow
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 89 (03) : 360 - 366
  • [9] Thyrotoxicosis after iodine fortification. A 21-year Danish population-based study
    Ma, Zheng Feei
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 89 (05) : 677 - 678
  • [10] Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab
    Karasek, David
    Cibickova, Lubica
    Karhanova, Marta
    Kalitova, Jana
    Schovanek, Jan
    Frysak, Zdenek
    [J]. ENDOKRYNOLOGIA POLSKA, 2017, 68 (05) : 498 - 504